Home/Filings/4/0001179110-21-006778
4//SEC Filing

Shearman Mark S 4

Accession 0001179110-21-006778

CIK 0001650664other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 4:19 PM ET

Size

7.1 KB

Accession

0001179110-21-006778

Insider Transaction Report

Form 4
Period: 2021-06-14
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2021-06-14+32,70132,701 total
  • Award

    Stock Option (right to buy)

    2021-06-14+52,71852,718 total
    Exercise: $38.53Exp: 2031-06-13Common Stock (52,718 underlying)
Footnotes (2)
  • [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025.
  • [F2]This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025.

Issuer

Editas Medicine, Inc.

CIK 0001650664

Entity typeother

Related Parties

1
  • filerCIK 0001643799

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 4:19 PM ET
Size
7.1 KB